Cargando…

Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib

BACKGROUND: Inhibition of metastasis of head and neck squamous cell carcinoma (HNSCC) is one of the most important challenges in cancer treatment. Src, a non-receptor tyrosine kinase, has been implicated as a key promoter in tumor progression and metastasis of HNSCC. However, Src therapy for HNSCC i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lang, Liwei, Shay, Chloe, Xiong, Yuanping, Thakkar, Parth, Chemmalakuzhy, Ron, Wang, Xuli, Teng, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011403/ https://www.ncbi.nlm.nih.gov/pubmed/29925404 http://dx.doi.org/10.1186/s13045-018-0623-3

Ejemplares similares

Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma
por: Lang, Liwei, et al.
Publicado: (2019)

Nck-associated protein 1 associates with HSP90 to drive metastasis in human non-small-cell lung cancer
por: Xiong, Yuanping, et al.
Publicado: (2019)

FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis
por: Lang, Liwei, et al.
Publicado: (2021)

SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma
por: Heusschen, Roy, et al.
Publicado: (2016)

Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo
por: Du, Guifang, et al.
Publicado: (2020)

Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis
por: He, Leilei, et al.
Publicado: (2019)

An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain
por: Danson, Sarah, et al.
Publicado: (2019)

Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
por: Williams, Eleanor, et al.
Publicado: (2021)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer
por: Arcaroli, John, et al.
Publicado: (2012)

The effects of Src tyrosine kinase inhibitor, saracatinib, on the markers of epileptogenesis in a mixed-sex cohort of adult rats in the kainic acid model of epilepsy
por: Rao, Nikhil S., et al.
Publicado: (2023)

Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer
por: Lang, Liwei, et al.
Publicado: (2021)

Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy
por: Sharma, Shaunik, et al.
Publicado: (2021)

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
por: Oswald, Ailsa J., et al.
Publicado: (2023)

Intracellular reduction in ATP levels contributes to CYT997‐induced suppression of metastasis of head and neck squamous carcinoma
por: Zhao, Xiangdong, et al.
Publicado: (2018)

Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
por: Lang, Liwei, et al.
Publicado: (2023)

An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)
por: Huang, R Y-J, et al.
Publicado: (2013)

Saracatinib, a Src Tyrosine Kinase Inhibitor, as a Disease Modifier in the Rat DFP Model: Sex Differences, Neurobehavior, Gliosis, Neurodegeneration, and Nitro-Oxidative Stress
por: Gage, Meghan, et al.
Publicado: (2021)

Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro
por: Shin, Jin Soo, et al.
Publicado: (2018)

Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants
por: Thompson, Summer L., et al.
Publicado: (2021)

ATAD3A mediates activation of RAS-independent mitochondrial ERK1/2 signaling, favoring head and neck cancer development
por: Lang, Liwei, et al.
Publicado: (2022)

Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity
por: Teng, Yong, et al.
Publicado: (2017)

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
por: McGivern, Niamh, et al.
Publicado: (2017)

PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines
por: Nakachi, I, et al.
Publicado: (2016)

Gut dysbiosis following organophosphate, diisopropylfluorophosphate (DFP), intoxication and saracatinib oral administration
por: Gage, Meghan, et al.
Publicado: (2022)

Post-status epilepticus treatment with the Fyn inhibitor, saracatinib, improves cognitive function in mice
por: Luo, Xin-Ming, et al.
Publicado: (2021)

Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics
por: Lang, Liwei, et al.
Publicado: (2017)

The Differential Impact of SRC Expression on the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma
por: Hermida-Prado, Francisco, et al.
Publicado: (2019)

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
por: Kaye, S, et al.
Publicado: (2012)

Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma
por: Liao, Xia, et al.
Publicado: (2020)

SDCBP Modulates Stemness and Chemoresistance in Head and Neck Squamous Cell Carcinoma through Src Activation
por: Mir, Cristina, et al.
Publicado: (2021)

Silver nanoparticle based multifunctional approach for combating COVID-19
por: Allawadhi, Prince, et al.
Publicado: (2021)

Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer
por: Byeon, Hyung Kwon, et al.
Publicado: (2019)

Survival after parotid gland metastases of cutaneous squamous cell carcinoma of the head and neck
por: Meyer, Moritz Friedo, et al.
Publicado: (2021)

Importance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts
por: Harrach, Saliha, et al.
Publicado: (2017)

Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway
por: Yang, Zejia, et al.
Publicado: (2019)

Management of neck metastases in head and neck cancer: United Kingdom National Multidisciplinary Guidelines
por: Paleri, V, et al.
Publicado: (2016)

Multifunctional ionic porous frameworks for CO(2) conversion and combating microbes
por: Hussain, MD. Waseem, et al.
Publicado: (2020)

CD133/Src Axis Mediates Tumor Initiating Property and Epithelial-Mesenchymal Transition of Head and Neck Cancer
por: Chen, Yu-Syuan, et al.
Publicado: (2011)

Hypoxia-Targeting Multifunctional Nanoparticles for Sensitized Chemotherapy and Phototherapy in Head and Neck Squamous Cell Carcinoma
por: Song, Chuanhui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9o7avbnh3o2rtjobno1bumm8fp